

## Treatment of Opioid Use Disorder

Jason Beaman, D.O., M.S., M.P.H., FAPA Interim Chair, School of Forensic Sciences Associate Clinical Professor Department of Psychiatry and Behavioral Sciences Oklahoma State University Center for Health Sciences



## Objectives

- Understand the behavioral treatment of OUD
- Understand medications for OUD
- Understand the use of an appropriate treatment plan

## Opioid Conditions

## Overdose

## Withdrawal

## **Opioid Use Disorder**

#### Treatment for Opioid Use Disorder

#### Behavioral alone

Medication Assisted Treatment alone

Combination of the above

### Behavioral Treatment

- Motivational Interviewing
- Individual psychotherapy
- Relapse prevention
- 12 Step groups



#### Motivational Interviewing



Engages patient in a nonconfrontational explorative conversation



#### Evaluates pros and cons



Primary modality for exploring change

## Individual Psychotherapy

- May help to explore underlying personality traits that can contribute to use
- Explore relationship problems to help increase insight and support



#### **Relapse Prevention**

- Recognition of people, places and things
- Relapse is a natural process of recovery
- If relapse occurs:
  - Increase treatment
  - Minimize extent and length of use

# People as a Trigger



## Places as a Trigger



## Things as a Trigger



### 12 Step Groups

- Varying evidence of efficacy
- Some individuals find it helpful

• Requires some basic religious acceptance

• Located around the world

### Medications Used for Opioid Use Disorder

## Methadone

## Buprenorphine

## Naltrexone


### MOUD


Not

MAT

Treatment Retention and Decreased Illicit Opioid Use with MOUD


 Buprenorphine promotes retention, and those who remain in treatment become more likely over time to abstain from other opioids






22

### Opioid Ligand Pharmacology



39

## Abstinence Without MAT



Hunt et al., 1971


Benefits of MAT: Decreased Mortality

**Death rates:** 

Dupouy et al., 2017

Evans et al., 2015

Sordo et al., 2017




Standardized Mortality Ratio

PC S S

23


Clinical Support

### The Goal is to Keep People Alive



### Methadone

- Can only be utilized in a federally qualified methadone clinic (Opioid Treatment Program; OTP)
- Provides the most amount of structure and monitoring
- Usually much lower doses than what is used for pain
- Associated with relatively low overdose
- OTP's can also dispense buprenorphine



Suboxone Subutex vs. Subutex is Buprenorphine alone Highly diverted • "mono-product" All Can provide euphoria prescriptions should be for depending on dose and route Suboxone

#### Subutex vs. Suboxone

Buprenorphine has very low bioavailability

Naloxone is not absorbed sublingually or buccally, but high absorption IV

So if Suboxone is injected, low chance of euphoria and very high chance of immediate withdrawal




### How to Use

- Initial dose should be at a level to stop withdrawal
  - Most individuals need to be at mild withdrawal, if not, Suboxone will cause it



- Eventually titrate to dose that curbs cravings, which may alter over time
- Progression to more home-based induction vs. office based


#### Buprenorphine Dosing: Efficacy






111

#### Mean Heroin Craving: 16 Week Completers: Reduced Craving with Therapeutic Buprenorphine Doses






112

P C S S Providers Clinical Support System

#### Buprenorphine Dosing: Safety

Cognitive and psychomotor effects appear to be negligible




Nearly all fatal poisonings involve multiple substances

Hakkinen et al., 2012 Walsh et al., 1994



116


#### Buprenorphine: Maintenance vs. Taper



113



### Benefits of Methadone: Treatment Retention



- ->- Buprenorphine (% = % of buprenorphine participants prescribed in that dose range)
- ↔ Methadone (% = % of methadone participants prescribed in that dose range)



Hser et al., 2014



### Naltrexone

- Usually extended released (XR)
- Monthly Injection
- Full opioid antagonist

Naltrexone


Must be opioid free (usually 7 days)

Do not want to precipitate opioid withdrawal

Cost could be prohibitive to many individuals

A good option for individuals that have failed opioid based medications

## Naltrexone: Dose Response



Comer et al., 2011

117



### Treatment Plan

- Should see frequently in the beginning of treatment
  - At least weekly
- Should use vigilance
  - UDS, PMP, etc.
- Should be multipmodel







Physicians should be aware of the condition their patient is experiencing

An evidenced based individualized treatment plan can help a person enter recovery

#### Questions

